Drug profile · INN
tezepelumab-ekko
TEZSPIRE
tezepelumab-ekko (TEZSPIRE) is a thymic stromal lymphopoietin inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — tezepelumab-ekko
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tezepelumab-ekko (TEZSPIRE) is a thymic stromal lymphopoietin inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Thymic stromal lymphopoietin inhibitor
Primary target: Thymic stromal lymphopoietin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is tezepelumab-ekko?
tezepelumab-ekko (TEZSPIRE) is a thymic stromal lymphopoietin inhibitor. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for tezepelumab-ekko?
TEZSPIRE is a marketed brand name for tezepelumab-ekko. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tezepelumab-ekko?
tezepelumab-ekko has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.